- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
‘Delta Plus’ Variant Surfaces in 8 U.S. States
U.S. health officials say they’re keeping close watch on a ‘Delta plus’ variant that’s been detected in at least eight states.
While the AY.4.2 “sub-lineage” of Delta may spread faster than the original variant, there’s no evidence that it causes more severe illness, and authorities say current vaccines remain effective against it, CBS News reported.
Lab tests have confirmed at least one case of AY.4.2 in each of the following states: California, Florida, Maryland, Massachusetts, Nevada, North Carolina, Rhode Island, Washington, and the District of Columbia.
While the U.S. Centers for Disease Control and Prevention estimates that AY.4.2 has accounted for less than 0.05% of circulating cases in the United States for several weeks, federal officials are tracking it closely.
“We have teams that are constantly reviewing the genetic sequence data and looking for blips, an increase in a certain proportion or just something that’s completely new,” Dr. Summer Galloway, executive secretary of the federal government’s SARS-CoV-2 Interagency Group, told CBS News.
Labs have started to prepare tests to assess whether AY.4.2 can evade antibodies from vaccinated people or from monoclonal antibody treatments, said Galloway, who is also policy lead on the CDC’s laboratory and testing task force.
“Right now, I think there’s not a lot that we know. But in terms of the risk that it poses to public health, the prevalence is very low in the U.S. and we don’t really anticipate that the substitutions [of AY.4.2] are going to have a significant impact on either the effectiveness of our vaccines or its susceptibility to monoclonal antibody treatments,” Galloway added.
AY.4.2 and previously identified sub-lineages of Delta called AY.1 and AY.2 are sometimes interchangeably called ‘Delta plus’ variants. Overall, the Delta variant and its sub-lineages have caused nearly 100% of cases in the United States for months, according to the CDC.
In the U.K., AY.4.2 now accounts for more than 11% of cases of the Delta variant, but officials say it does not appear to have caused a “significant reduction” in vaccine effectiveness or an increase in hospitalizations,CBS News reported.
However, it could be spreading faster due to “slightly increased biological transmissibility,” according to a report from the U.K. Health Security Agency.
More information
Visit the U.S. Centers for Disease Control and Prevention for more on COVID variants.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.